- Home
- DNLI
as 12-18-2024 1:35pm EST
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.3B | IPO Year: | 2017 |
| Target Price: | $40.40 | AVG Volume (30 days): | 784.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.56 - $33.33 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | 204.74% |
| Revenue Growth (this year): | -96.83% | Revenue Growth (next year): | 420.35% |
Stock Insider Trading Activity of Denali Therapeutics Inc. (DNLI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schenkein David P | DNLI | Director | Nov 11 '24 | Sell | $32.48 | 59,441 | $1,932,665.05 | 41,532 | |
| Schuth Alexander O. | DNLI | COFO and Secretary | Nov 7 '24 | Sell | $30.56 | 15,558 | $465,286.44 | 181,291 | |
| SATO VICKI L | DNLI | Director | Nov 7 '24 | Sell | $30.00 | 1,020 | $30,600.00 | 111,056 | |
| SATO VICKI L | DNLI | Director | Nov 1 '24 | Sell | $27.07 | 3,080 | $83,375.60 | 111,056 | |
| Watts Ryan J. | DNLI | President and CEO | Oct 18 '24 | Sell | $27.69 | 40,000 | $1,107,600.00 | 235,807 | |
| Krognes Steve E. | DNLI | Director | Sep 30 '24 | Sell | $29.03 | 30,000 | $870,900.00 | 29,096 |
Latest Denali Therapeutics Inc. News
DNLI Breaking Stock News: Dive into DNLI Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Denali Therapeutics upgraded to Buy from Hold at Stifel
MT Newswires
2 days ago
Stifel Nicolaus Upgrades Denali Therapeutics to Buy From Hold, Raises Price Target to $37 From $28
Zacks
12 days ago
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Zacks
12 days ago
Denali Starts Dosing in Phase II Parkinson's Disease Study
GlobeNewswire
13 days ago
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
MT Newswires
21 days ago
B. Riley Raises Price Target on Denali Therapeutics to $38 From $33, Keeps Buy Rating
Simply Wall St.
a month ago
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
MT Newswires
a month ago
Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing
Compare DNLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNLI Denali Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.